Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-06-10
2008-06-10
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S649000, C514S651000, C564S280000
Reexamination Certificate
active
07384983
ABSTRACT:
The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.
REFERENCES:
patent: 4314081 (1982-02-01), Molloy et al.
patent: 2004/0082666 (2004-04-01), Mattiuz et al.
patent: 0303961 (1989-02-01), None
patent: WO02070457 (2002-09-01), None
Ring et al,Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism, Drug Metabolism and Disposition, 2001, vol. 30 No. 3, 319-23.
Farid, et al. (1985) “Single-Dose and Steady-State Pharmacokinetics of Tomoxetine in Normal Subjects”J Clin Pharmacol; 25: 296-301.
Ring, et al. (2001) “Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism”Drug Metabolism and Disposition; vol. 30, No. 3: 319-323.
Mattiuz Edward Louis
Sauer John-Michael
Wheeler William Joe
Wong David Taiwai
Cohen Charles E.
Eli Lilly and Company
Pryor Alton
Stemerick David M.
LandOfFree
Inhibitor of monoamine uptake does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitor of monoamine uptake, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of monoamine uptake will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807215